// App-Quantinova.ai

CTNI-36 : INITIATION OF A PHASE 1 DOSE-ESCALATING STUDY OF WEEKLY DIRECT-TO-BRAIN ADMINISTRATION OF SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (MAGIC-G1 STUDY)

Researchers

Presenter

  • Annick Desjardins

Principal Investigators

  • Kelly Conlon

  • Hannah Gunning

  • Rhian Davies

  • Jordan Komisarow

  • Robert Cavaliere

  • Dmitry Zamoryakhin

Medical Centers

  • The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, USA

  • Midatech Pharma Ltd, Cardiff, United Kingdom

  • Baptist MD Anderson, Jacksonville, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Central Nervous System (CNS)

Disease

  • Diffuse intrinsic pontine glioma

  • Glioblastoma

  • Cerebral metastases

  • Gliomas

Biomarkers

  • Transforming growth factor beta

Drug/Treatment

  • Panobinostat

  • Lomustine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved